19 / 25
Journal of Transmitted Diseases and Immunity
ISSN: 2573-0320
Page 51
Volume 4
May 10-11, 2018
Frankfurt, Germany
Immunology Research 2018
Tissue Science 2018
JOINT EVENT
2 2
n d
E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n
Immunology and
Evolution of Infectious Diseases
&
1 2
t h
E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n
Tissue Engineering and
Regenerative Medicine
A
t present, despite long lasting efforts, a harmless, effective
artificial oxygen carrier is missing for clinical use both in
Europe and USA. To bypass this bottleneck albumin-derived
perfluorocarbon-based nanocapsules (nanocapsules) were
designed as a novel artificial oxygen carrier. Nanocapsules do
not contain any chemical emulsifier and can be synthesized in
different size ranges (Ø 100-1500 nm). Physical assessment
of size, oxygen transport capacity and repeated loading and
unloading of respiratory gases was already performed and
in vitro
functionality was successfully proven using a flow-controlled
Langendorff heart. Functionality
in vivo
was shown using a
normovolemic hemodilution model. Up to 95% of the blood (final
hematocrit of ~5%) was exchanged stepwise against plasma-like
medium with nanocapsules (treatment) or without nanocapsules
(control) in order to dilute below the critical hematocrit of a rat
(~10%). Rats were monitored throughout the experiment (e.g.
heart rate, mean arterial pressure (MAP), body core temperature
and blood gas analysis). Furthermore rat kidneys were assessed
for expression of erythropoietin using RNA scope technique to
track effects of oxygen shortage on cellular level. Compared to
control group all animals of the treatment group survived longer,
showed a significant higher MAP and presented a continuous
physiological temperature. Importantly, within the observation
period erythropoietinmRNAwas detected only in control animals.
In conclusion nanocapsules provide enough oxygen to supply an
organismwhen erythrocytes are not sufficiently present anymore,
whereas plasma-like medium fails in the absence of any oxygen
carrier. These positive results are confirmed on cellular level with
the oxygen-dependent presence of erythropoietin.
Biography
Katja Bettina Ferenz has completed her PhD in Pharmaceutical Chemistry
from Westfaelische-Wilhelms-University Muenster in Germany. From 2011
to 2018, she led her own research group development of artificial oxygen
carriers at University Hospital Essen, Institute of Physiological Chemistry,
Germany. Since February 2018, she continues her research on artificial
blood and organ regeneration as Assistant Professor at University Hospital
Essen, Institute of Physiology. Since 2017, she is a member of the editorial
boards for the
Journal of Nanochemistry and Nanotechnology and Journal of
Nanoscience and Nanomedicine
. Her research interests are artificial oxygen
carriers, regeneration of tissue/organs, micro- and nanoparticles, nanomed-
icine, perfluorocarbons, drug delivery and biomaterials.
katja.ferenz@uni-due.deFunctionality of perfluorodecalin-based artificial
oxygen carriers: impact on the whole organism and on
cellular level
Katja Bettina Ferenz
1
, Anna Wrobeln
2
, Timm Schreiber
2
, Joachim Fandrey
2
,
Alexandra Scheer
2
and
Michael Kirsch
2
1
University Hospital Essen, Germany
2
University of Duisburg-Essen, Germany
Katja Bettina Ferenz et al., J Transm Dis Immun 2018, Volume 2
DOI: 10.21767/2573-0320-C2-005